Is Affimed NV overvalued or undervalued?
As of November 14, 2024, Affimed NV is considered overvalued with a valuation grade of "does not qualify," reflecting significant financial challenges, including a -395.01% return on equity and a 98.47% stock decline over the past year, underperforming the S&P 500's 10.26% return.
As of 14 November 2024, Affimed NV's valuation grade has moved from risky to does not qualify, indicating a significant deterioration in its financial health. The company is currently considered overvalued given its negative financial metrics, including a price-to-book value of 0.05 and an EV to EBITDA ratio of 0.21. The return on equity stands at a staggering -395.01%, highlighting the challenges the company faces in generating profits.When compared to peers, Affimed NV's valuation appears unfavorable. For instance, Kodiak Sciences, Inc. also does not qualify but has a more manageable EV to EBITDA ratio of -0.9313, while Compugen Ltd. is rated risky with an EV to EBITDA of -3.4456. The stark contrast in these ratios suggests that Affimed NV is not only struggling but is also overvalued relative to its peers. Additionally, the company's stock has plummeted 98.47% over the past year, significantly underperforming the S&P 500, which returned 10.26% in the same period.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
